Oregon Health & Science University Hospital and Clinics Provider's Orders	ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE Patient Identification IN INK WITH A CHECKMARK ( ✓ ) TO BE ACTIVE.			
Weight:				
Treatment Start Date: Patient to follow up with provider on date:				

# **GUIDELINES FOR ORDERING**

- 1. Ferumoxytol is contraindicated in patients with a history of allergic reaction to any intravenous iron product.
- 2. Provider must order and obtain a ferritin prior to patient being scheduled for iron infusion. Labs drawn date: \_\_\_\_\_
- 3. Ferumoxytol administration may alter magnetic resonance (MR) imaging, conduct anticipated MRI studies prior to use.
- 4. MR imaging alterations may persist for less than or equal to 3 months following use, with peak alterations anticipated in the first 2 days following administration.
- 5. If MR imaging is required within 3 months after administration, use T1- or proton density-weighted MR pulse sequences to decrease effect on imaging.
- 6. Do not use T2-weighted sequence MR imaging prior to 4 weeks following ferumoxytol administration.

# NURSING ORDERS:

- 1. TREATMENT PARAMETERS Hold treatment and notify provider if Ferritin greater than 300 ng/mL.
- 2. VITAL SIGNS For Ferumoxytol infusion: Monitor and record vital signs at conclusion of infusion and immediately prior to discharge.
- 3. Patient may experience hypotension during infusion, ensure patient is in a reclined or semi-reclined position during the ferumoxytol infusion.
- 4. Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following infusion. Hypersensitivity reactions have occurred in patients in whom a previous ferumoxytol dose was tolerated.
- 5. Instruct patient to set follow up appointment with provider for follow up labs.
- 6. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.

## **MEDICATIONS:** (select one)

ferumoxytol (FERAHEME) in sodium chloride 0.9 %, intravenous, administer over 15 minutes 510 mg, x 2 doses, Administer dose followed by repeat dose 3-8 days after.

## AS NEEDED MEDICATIONS:

1. sodium chloride 0.9%, 500 mL, intravenous, AS NEEDED x1 dose for vein discomfort. Give concurrently with ferumoxytol

OHSU Health	Oregon Health & Science University Hospital and Clinics Provider's Orders ADULT AMBULATORY INFUSION ORDER Ferumoxytol (FERAHEME) Infusion	ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE
	Page 2 of 3	Patient Identification
ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( $\checkmark$ ) to be active		

## HYPERSENSITIVITY MEDICATIONS:

- NURSING COMMUNICATION If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
- NURSING COMMUNICATION Avoid intravenous or oral diphenhydrAMINE, move to next option in the algorithm. Adverse effects of diphenhydrAMINE may overlap with IV iron adverse effects such as flushing, hypotension, tachycardia.
- 3. EPINEPHrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

# By signing below, I represent the following:

I am responsible for the care of the patient (*who is identified at the top of this form*); I hold an active, unrestricted license to practice medicine in: *Check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon*);

## My physician license Number is # \_

(MUST BE COMPLETED TO BE A VALID

**PRESCRIPTION)**; and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature:	Date/Time:	Date/Time:	
Printed Name:	Phone:	Fax:	

	Oregon Health & Science University Hospital and Clinics Provider's Orders	ACCOUNT NO.
OHSU	ADULT AMBULATORY INFUSION ORDER	MED. REC. NO.
Health Ferumoxytol (FERAHEME) Infusion	NAME	
	BIRTHDATE	
	Page 3 of 3	Patient Identification
ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( $\checkmark$ ) TO BE ACTIVE.		

# Central Intake:

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

## Please check the appropriate box for the patient's preferred clinic location:

#### □ Beaverton

OHSU Knight Cancer Institute 15700 SW Greystone Court Beaverton, OR 97006 Phone number: 971-262-9000 Fax number: 503-346-8058

#### □ NW Portland

Legacy Good Samaritan campus Medical Office Building 3, Suite 150 1130 NW 22nd Ave Portland, OR 97210 Phone number: 971-262-9600 Fax number: 503-346-8058

# Gresham

Legacy Mount Hood campus Medical Office Building 3, Suite 140 24988 SE Stark Gresham, OR 97030 Phone number: 971-262-9500 Fax number: 503-346-8058

# Tualatin

Legacy Meridian Park campus Medical Office Building 2, Suite 140 19260 SW 65th Ave Tualatin, OR 97062 Phone number: 971-262-9700 Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders